Media Center

In the media

AbilityPharma capta 5 M€ per a un assaig contra el càncer de pàncreas

ARA

25/03/2020

+ info

Ability Pharma receives the acknowledgement from Cerdanyola Empresarial

Parc UAB newsletter

22/11/2019

+ info

Ability reinforces the direction and rises 2 million euros from Inveready and Everis

Expansión

13/09/2019

+ info

Ability Pharma rises 3.5M€ to finish the clinical trial in cancer

Ara

13/09/2019

+ info

A Catalan drug can extend the life expectancy of patients with lung and endometrial cancer

RAC1

06/06/2019

+ info

Nine Catalan biotechs among the most promising in Europe

La Vanguardia

28/05/2019

+ info

AbilityPharma will start research for cancer in China

El Punt Avui

05/02/2019

+ info

The partner of AbilityPharma in China starts clinical trials with the licensed drug

Expansión

04/02/2019

+ info

AbilityPharma rises 1.2M euros with the biggest round of Capitall Cell

Ara

10/12/2018

+ info

AbilityPharma recibe su tercera designación de medicamento huérfano por la FDA

Expansión

08/11/2018

+ info

TechShare, el programa que abre las puertas de la Bolsa a las pymes biotech

Innovaspain

26/09/2018

+ info

Cómo facilitar la salida a bolsa de empresas biotecnológicas

Diario Medico

26/09/2018

+ info

ABILITY PHARMA COMENÇA LA FASE 2 DEL SEU NOU ANTICANCERIGEN

La Vanguardia

20/09/2018

+ info

ABILITYPHARMA ABRE UNA RONDA PARA LUCHAR CONTRA EL CÁNCER

Expansión

13/09/2018

+ info

The FDA approves a clinical trial of AbilityPharma

Expansión

20/02/2018

+ info

Ability Pharma gets FDA nod for a new clinical trials

Diari de Sabadell

20/02/2018

+ info

Ability receives FDA authorization to start clinical trials

Expansión

14/12/2017

+ info

Ability Pharma seeks 2.5 million to expand clinical trials

Expansión

09/10/2017

+ info

Ability Pharma receives the OK from France for testing a new drug

Diari Sabadell

09/10/2017

+ info

ABILITY PHARMA ACHIEVES THE DISTINCTION OF ORPHAN DRUG IN THE EU

Expansión

19/09/2017

+ info

LATEST NEWS

25.03.2020

News

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

News

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

News

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

News

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

News

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
Clinical stage drug discovery and development
biopharmaceutical company headquartered in
Cerdanyola del Vallès (Barcelona), Catalonia, Spain.
Home About us Our team R&D Business Development Media Center
Avinguda Parc Tecnològic, 3
Centre d’Empreses de Noves Tecnologies
Parc Tecnològic del Vallès
08290 Cerdanyola (Barcelona)
Catalonia – Spain contact@abilitypharma.com
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG

Carretera antiga Amer nº 10
17007 • Girona
T. 972 909 999
E. info@neorgsite.com
http://www.neorgsite.com